Symphogen
Mads Laustsen has extensive experience in the biotechnology industry, currently serving as the Chief Manufacturing Officer at Symphogen since June 2014. Prior to this role, Mads Laustsen was the CEO of CMC Biologics from 2001 to 2014, where leadership and strategic direction were key responsibilities. This background showcases a strong foundation in executive management and manufacturing operations within the biopharmaceutical sector.
Symphogen
3 followers
Symphogen is a clinical-stage antibody oncology focused company with a differentiated product pipeline and significant commercial opportunities. Inspired by nature, led by science and driven by people, we passionately strive to make that discovery that may have great effect on the lives of patients, their families, and their caregivers. Based on our monoclonal antibody (mAb) research platform, we create differentiated mAb and mAb mixture products candidates. Our pre-clinical and clinical pipeline is well suited for a precision-medicine approach by addressing well-defined, biomarker-selected patient populations. We are headquartered in Denmark with operations in the US.